{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:51:32Z","timestamp":1794448292822,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T00:00:00Z","timestamp":1376611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.clinthera.2013.08.003","type":"journal-article","created":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T22:01:17Z","timestamp":1379541677000},"page":"1571-1581","source":"Crossref","is-referenced-by-count":57,"title":["Tolerability and Pharmacokinetic Properties of Ciprofloxacin Dry Powder for Inhalation in Patients With Cystic Fibrosis: A\u00a0Phase I, Randomized, Dose-Escalation Study"],"prefix":"10.1016","volume":"35","clinical-trial-number":[{"clinical-trial-number":"2006-003690-26","registry":"10.18810\/euctr"}],"author":[{"given":"Heino","family":"Stass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Weimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Nagelschmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rolinck-Werninghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Staab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.08.003_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000029453","article-title":"Pathogenesis of lung disease in cystic fibrosis","volume":"67","author":"Dinwiddie","year":"2000","journal-title":"Respiration"},{"key":"10.1016\/j.clinthera.2013.08.003_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2013.08.003_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1378\/chest.08-0776","article-title":"Bronchiectasis","volume":"134","author":"O\u2019Donnell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2013.08.003_bib4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1183\/09031936.05.00050304","article-title":"Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre","volume":"25","author":"Van Daele","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2013.08.003_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jcf.2009.08.003","article-title":"Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985\u20132005","volume":"8","author":"Millar","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2013.08.003_bib6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2013.08.003_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.rmed.2008.09.024","article-title":"Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis","volume":"103","author":"Amadori","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2013.08.003_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2013.08.003_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/COPD.S6133","article-title":"The pathophysiology of bronchiectasis","volume":"4","author":"King","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2013.08.003_bib10","first-page":"836","article-title":"Inhaled antimicrobial therapy: from cystic fibrosis to the flu","volume":"45","author":"O\u2019Riordan","year":"2000","journal-title":"Respir Care"},{"key":"10.1016\/j.clinthera.2013.08.003_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1569-1993(02)00002-4","article-title":"Inhaled antibiotic therapy: what drug? What dose? What regimen? What formulation?","volume":"1","author":"Smith","year":"2002","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2013.08.003_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1586\/17476348.2.4.479","article-title":"Aerosolized antibiotics in cystic fibrosis: current and future trends","volume":"2","author":"Fiel","year":"2008","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.clinthera.2013.08.003_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ers.11.56","article-title":"Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"5","author":"Parkins","year":"2011","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.clinthera.2013.08.003_bib14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2013.08.003_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2013.08.003_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1128\/AAC.25.3.331","article-title":"In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent","volume":"25","author":"Eliopoulos","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.08.003_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur Respir J"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2013.08.003_bib18","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60100-9","article-title":"Pharmacokinetics of ciprofloxacin PulmoSphere inhalational powder","volume":"7","author":"Stass","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"Suppl 31","key":"10.1016\/j.clinthera.2013.08.003_bib19","first-page":"300","article-title":"Safety and pharmacokinetics of inhaled drug powder ciprofloxacin after single and multiple inhalations in patients with cystic fibrosis","volume":"43","author":"Stass","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2013.08.003_bib20","unstructured":"Endermann R, Labischinski H., Ladel C., et al. Inventors treatment of bacterial diseases of the respiratory organs. US patent 2004\/0254194 A1. 2004."},{"key":"10.1016\/j.clinthera.2013.08.003_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1023\/A:1007513213292","article-title":"Hollow porous particles in metered dose inhalers","volume":"17","author":"Dellamary","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2013.08.003_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1378\/chest.124.1.360","article-title":"Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers","volume":"124","author":"Newhouse","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2013.08.003_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology","volume":"24","author":"Geller","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.clinthera.2013.08.003_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1183\/09031936.03.00043603","article-title":"Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL","volume":"22","author":"Reinhardt","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2013.08.003_bib25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/AAC.30.3.444","article-title":"Absolute oral bioavailability of ciprofloxacin","volume":"30","author":"Drusano","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.08.003_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.31.6.956","article-title":"Effect of dose size on bioavailability of ciprofloxacin","volume":"31","author":"Plaisance","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.08.003_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2013.08.003_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.28.2.235","article-title":"Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers","volume":"28","author":"Gonzalez","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.08.003_bib29","unstructured":"Bayer Healthcare AG. Cipro IV for intravenous infusion (intravenous ciprofloxacin) [summary of product characteristics]. http:\/\/www.medicines.org.uk\/emc\/medicine\/2536\/SPC. Accessed December 13, 2012"},{"key":"10.1016\/j.clinthera.2013.08.003_bib30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4155\/tde.11.19","article-title":"Flip-flop pharmacokinetics\u2014delivering a reversal of disposition: challenges and opportunities during drug development","volume":"2","author":"Yanez","year":"2011","journal-title":"Ther Deliv"},{"key":"10.1016\/j.clinthera.2013.08.003_bib31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1128\/AAC.26.5.741","article-title":"Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers","volume":"26","author":"Gonzalez","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.08.003_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/46.5.669","article-title":"Application of fluoroquinolone pharmacodynamics","volume":"46","author":"Wright","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2013.08.003_bib33","unstructured":"Bayer Pharmaceuticals. Cipro (ciprofloxacin hydrochloride) tablets, Cipro (ciprofloxacin) oral suspension [product information]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/19537s049,19857s031,19847se5-027,20780se5-013_cipro_lbl.pdf. Accessed December 13, 2012."},{"key":"10.1016\/j.clinthera.2013.08.003_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003495-199958002-00006","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"58","author":"Turnidge","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2013.08.003_bib35","unstructured":"European Committee on Antimicrobial Susceptibility Testing. MIC distributions. http:\/\/www.eucast.org\/mic_distributions\/. Accessed January 1, 2011."},{"key":"10.1016\/j.clinthera.2013.08.003_bib36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4187\/aarc0537","article-title":"Aerosol antibiotics in cystic fibrosis","volume":"54","author":"Geller","year":"2009","journal-title":"Respir Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813008795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813008795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T15:08:47Z","timestamp":1584112127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813008795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0149291813008795"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.08.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}